| |
Tuesday, December 6, 2022 | 12pm ET/9am PT Biopharma customers are now demanding that the vendor industry work collaboratively to connect their scientific workflows. This webinar will provide valuable insights for biopharmaceutical scientists, lab directors, IT professionals, and life science vendors. Register now. 
|
|
Today's Big NewsNov 22, 2022 |
|
Tuesday, December 6, 2022 | 10am ET / 7am PT The development of therapeutic antibodies has been challenged by the difficulty to generate such intricate molecules. Here, we show that ProBio has established proprietary fast CMC platform guaranteeing the delivery of monoclonal antibody with high titer. Register now. 
|
|
| By Angus Liu GSK is setting a new standard for speed when it comes to withdrawing an accelerated approval after a confirmatory trial failure. The British drugmaker is pulling Blenrep off the U.S. market just 15 days after announcing a phase 3 flop. The move comes despite potentially imminent readouts from two other phase 3 trials. |
|
|
|
By Heather Landi On the heels of several high-profile healthcare acquisitions, Walgreens aims to be a point of entry for consumers for healthcare services ranging from urgent care to specialty care and even in-home health. |
By Conor Hale "Slower than predicted procedure and supply recovery drove revenue below our expectations this quarter,” said CEO Geoff Martha. |
By Nick Paul Taylor Pfizer’s $1 billion bet on Arvinas’ protein degradation technology has delivered phase 2 data. After a publication snafu, Arvinas posted the breast cancer results ahead of schedule—and revealed one partial response among 35 patients at its phase 3 dose. |
|
Tuesday, December 7th, 2022 | 10am ET/7am PT In this presentation we’ll review how we established GOCHO™ cells from an adherent CHO-K1 cell line to meet current industry standards, how the choice of cloning media drove cell culture media choices for the entire cell-line development process, and more. Register now. 
|
|
By Kevin Dunleavy The courtroom drama surrounding Bristol Myers Squibb and its subsidiary Celgene over their efforts to restrict competition for lymphoma drug Revlimid has raged for more than a decade. And it's not going away any time soon, as three union pension funds have brought a class action antitrust suit against Bristol Myers and a raft of generic drugmakers. |
By Dave Muoio Akram Boutros, M.D., who has repaid the money with interest, was terminated with cause shortly before his planned retirement. He said that a statement released by MetroHealth's board chair detailing his undisclosed self payments "is full of misinformation and outright lies" and now threatens the four-hospital system with a lawsuit for "retaliatory" behavior. |
By Max Bayer Gamida Cell will need to wait a while longer to know whether regulators greenlight its stem cell transplant therapy, with the FDA extending the review period for the approval application by three months. The company said recent data provided to the FDA was considered a major amendment, prompting the extension. |
By Andrea Park More than half of Teleflex's restructuring costs—between $18 million and $22 million—will come from termination benefits paid out to laid-off employees. |
By Angus Liu BeiGene has shared detailed results from a Brukinsa head-to-head trial, and it’s bad news for rival Imbruvica from AbbVie and Johnson & Johnson. The latest update makes Brukinsa the first BTK inhibitor to top Imbruvica on a hard efficacy endpoint. |
By Robert King Leaders of the House Ways and Means Committee are pressing the Biden administration to change a rule that implements the arbitration process as part of a ban on surprise medical bills. |
By Andrea Park Masimo has declared racial bias a non-issue in its flagship SET pulse oximeter: Study results published this month found no clinically significant difference in the device’s accuracy when used on both Black and white patients. |
By James Waldron With all the talk of drugmakers cutting pipelines and laying off staff, it’s good to occasionally report on some investment back into the sector. For Novo Nordisk, that means investing 5.4 billion Danish kroner ($74 million) to boost R&D manufacturing needed for its clinical trials. |
By Fraiser Kansteiner Shionogi’s Xocova COVID-19 approval marks the first green light for a drug under Japan’s new emergency regulatory approval system. Shionogi is also angling for approval of its antiviral pill in the United States. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we share this week's headlines and discuss the 2022 honorees in our annual Fiercest Women in Life Sciences report. |
|
|---|
|
|
|
Tuesday, December 6, 2022 | 2pm ET / 11am PT In this webinar, we will cover how interoperability between EMS and the hospital can help elevate patient care while maximizing hospital revenue and how you can leverage your relationships with EMS to help manage and treat your most critical patients. Register Now. 
|
|
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| |
|
